Patents by Inventor Sean M. Dalziel
Sean M. Dalziel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9290491Abstract: The invention provides a crystalline sulfate salt of 3-endo-(8-{2-[cyclohexylmethyl-((S)-2,3-dihydroxy-propionyl)amino]ethyl}-8-aza-bicyclo[3.2.1]oct-3-yl)benzamide or a solvate thereof. The invention also provides pharmaceutical compositions comprising such crystalline salt forms, methods of using such crystalline salt forms to treat diseases associated with mu opioid receptor activity, and processes useful for preparing such crystalline salt forms.Type: GrantFiled: July 16, 2014Date of Patent: March 22, 2016Assignee: Theravance Biopharma R&D IP, LLCInventors: Sean M. Dalziel, Leticia M. Preza, Miroslav Rapta, Pierre-Jean Colson
-
Publication number: 20150073014Abstract: The invention provides a crystalline sulfate salt of 3-endo-(8-{2-[cyclohexylmethyl-((S)-2,3-dihydroxy-propionyl)amino]ethyl}-8-aza-bicyclo[3.2.1]oct-3-yl)benzamide or a solvate thereof. The invention also provides pharmaceutical compositions comprising such crystalline salt forms, methods of using such crystalline salt forms to treat diseases associated with mu opioid receptor activity, and processes useful for preparing such crystalline salt forms.Type: ApplicationFiled: July 16, 2014Publication date: March 12, 2015Applicant: THERAVANCE BIOPHARMA R&D IP, LLCInventors: Sean M. Dalziel, Leticia M. Preza, Miroslav Rapta, Pierre-Jean Colson
-
Patent number: 8969367Abstract: The invention provides crystalline solid forms of (S)-4-((2S,3S)-7-carbamoyl-1,1-diethyl-3-methoxy-1,2,3,4-tetrahydronaphthalen-2-ylamino)-2-cyclohexylmethyl-butyric acid. The invention also provides pharmaceutical compositions comprising such crystalline solid forms, methods of using such crystalline solid forms to treat diseases associated with mu opioid receptor activity, and processes useful for preparing such crystalline solid forms.Type: GrantFiled: June 17, 2013Date of Patent: March 3, 2015Assignee: Theravance Biopharma R&D IP, LLCInventors: Sean M. Dalziel, Miroslav Rapta
-
Publication number: 20130345466Abstract: The invention provides crystalline solid forms of (S)-4-((2S,3S)-7-carbamoyl-1,1-diethyl-3-methoxy-1,2,3,4-tetrahydronaphthalen-2-ylamino)-2-cyclohexylmethyl-butyric acid. The invention also provides pharmaceutical compositions comprising such crystalline solid forms, methods of using such crystalline solid forms to treat diseases associated with mu opioid receptor activity, and processes useful for preparing such crystalline solid forms.Type: ApplicationFiled: June 17, 2013Publication date: December 26, 2013Applicant: THERAVANCE, INC.Inventors: Sean M. Dalziel, Miroslav Rapta
-
Patent number: 8536335Abstract: The invention provides a crystalline sulfate salt of 3-endo-(8-{2-[cyclohexylmethyl-((S)-2,3-dihydroxy-propionyl)amino]ethyl}-8-aza-bicyclo[3.2.1]oct-3-yl)benzamide or a solvate thereof. The invention also provides pharmaceutical compositions comprising such crystalline salt forms, methods of using such crystalline salt forms to treat diseases associated with mu opioid receptor activity, and processes useful for preparing such crystalline salt forms.Type: GrantFiled: July 17, 2012Date of Patent: September 17, 2013Assignee: Theravance, Inc.Inventors: Sean M. Dalziel, Leticia M. Preza, Miroslav Rapta, Pierre-Jean Colson
-
Patent number: 8486958Abstract: The invention provides crystalline solid forms of (S)-4-((2S,3S)-7-carbamoyl-1,1-diethyl-3-methoxy-1,2,3,4-tetrahydronaphthalen-2-ylamino)-2-cyclohexylmethyl-butyric acid. The invention also provides pharmaceutical compositions comprising such crystalline solid forms, methods of using such crystalline solid forms to treat diseases associated with mu opioid receptor activity, and processes useful for preparing such crystalline solid forms.Type: GrantFiled: October 29, 2012Date of Patent: July 16, 2013Assignee: Theravance, Inc.Inventors: Sean M. Dalziel, Miroslav Rapta
-
Publication number: 20130072515Abstract: The invention provides a crystalline sulfate salt of 3-endo-(8-{2-[cyclohexylmethyl-((S)-2,3-dihydroxy-propionypamino]ethyl}-8-aza-bicyclo[3.2.1]oct-3-yl) benzamide or a solvate thereof. The invention also provides pharmaceutical compositions comprising such crystalline salt forms, methods of using such crystalline salt forms to treat diseases associated with mu opioid receptor activity, and processes useful for preparing such crystalline salt forms.Type: ApplicationFiled: July 17, 2012Publication date: March 21, 2013Applicant: THERAVANCE, INC.Inventors: Sean M. DALZIEL, Leticia M. PREZA, Miroslav RAPTA, Pierre-Jean COLSON
-
Publication number: 20130065916Abstract: The invention provides crystalline solid forms of (S)-4-((2S,3S)-7-carbamoyl-1,1-diethyl-3-methoxy-1,2,3,4-tetrahydronaphthalen-2-ylamino)-2-cyclohexylmethyl-butyric acid. The invention also provides pharmaceutical compositions comprising such crystalline solid forms, methods of using such crystalline solid forms to treat diseases associated with mu opioid receptor activity, and processes useful for preparing such crystalline solid forms.Type: ApplicationFiled: October 29, 2012Publication date: March 14, 2013Applicant: THERAVANCE, INC.Inventors: Sean M. Dalziel, Miroslav Rapta
-
Patent number: 8324236Abstract: The invention provides crystalline solid forms of (S)-4-((2S,3S)-7-carbamoyl-1,1-diethyl-3-methoxy-1,2,3,4-tetrahydronaphthalen-2-ylamino)-2-cyclohexylmethyl-butyric acid. The invention also provides pharmaceutical compositions comprising such crystalline solid forms, methods of using such crystalline solid forms to treat diseases associated with mu opioid receptor activity, and processes useful for preparing such crystalline solid forms.Type: GrantFiled: December 19, 2011Date of Patent: December 4, 2012Assignee: Theravance, Inc.Inventors: Sean M. Dalziel, Miroslav Rapta
-
Patent number: 8288550Abstract: The invention provides crystalline forms of the novel benzimidazole-carboxamide 5-HT4 receptor agonist compound, 4-(4-{[(2-isopropyl-1H-benzoimidazole-4-carbonyl)amino]methyl}-piperidin-1-ylmethyl)piperidine-1-carboxylic acid methyl ester. The invention also provides pharmaceutical compositions comprising the crystalline compound, methods of using the compound to treat diseases associated with 5-HT4 receptor activity, and processes useful for preparing crystalline forms of the compound.Type: GrantFiled: November 17, 2010Date of Patent: October 16, 2012Assignee: Theravance, Inc.Inventors: Sean M. Dalziel, Kirsten M. Phizackerley
-
Patent number: 8247555Abstract: The invention provides a crystalline sulfate salt of 3-endo-(8-{2-[cyclohexylmethyl-((S)-2,3-dihydroxy-propionyl)amino]ethyl}-8-aza-bicyclo[3.2.1]oct-3-yl)benzamide or a solvate thereof. The invention also provides pharmaceutical compositions comprising such crystalline salt forms, methods of using such crystalline salt forms to treat diseases associated with mu opioid receptor activity, and processes useful for preparing such crystalline salt forms.Type: GrantFiled: April 6, 2011Date of Patent: August 21, 2012Assignee: Theravance, Inc.Inventors: Sean M. Dalziel, Leticia M. Preza, Miroslav Rapta, Pierre-Jean Colson
-
Publication number: 20120088834Abstract: The invention provides crystalline solid forms of (S)-4-((2S,3S)-7-carbamoyl-1,1-diethyl-3-methoxy-1,2,3,4-tetrahydronaphthalen-2-ylamino)-2-cyclohexylmethyl-butyric acid. The invention also provides pharmaceutical compositions comprising such crystalline solid forms, methods of using such crystalline solid forms to treat diseases associated with mu opioid receptor activity, and processes useful for preparing such crystalline solid forms.Type: ApplicationFiled: December 19, 2011Publication date: April 12, 2012Applicant: THERAVANCE, INC.Inventors: Sean M. Dalziel, Miroslav Rapta
-
Patent number: 8101794Abstract: The invention provides crystalline solid forms of (S)-4-((2S,3S)-7-carbamoyl-1,1 -diethyl-3-methoxy-1,2,3,4-tetrahydronaphthalen-2-ylamino)-2-cyclohexylmethyl-butyric acid. The invention also provides pharmaceutical compositions comprising such crystalline solid forms, methods of using such crystalline solid forms to treat diseases associated with mu opioid receptor activity, and processes useful for preparing such crystalline solid forms.Type: GrantFiled: December 9, 2009Date of Patent: January 24, 2012Assignee: Theravance, Inc.Inventors: Sean M. Dalziel, Miroslav Rapta
-
Publication number: 20110201644Abstract: The invention provides crystalline forms of the novel benzimidazole-carboxamide 5-HT4 receptor agonist compound, 4-(4-{[(2-isopropyl-1H-benzoimidazole-4-carbonyl)amino]methyl}-piperidin-1-ylmethyl)piperidine-1-carboxylic acid methyl ester. The invention also provides pharmaceutical compositions comprising the crystalline compound, methods of using the compound to treat diseases associated with 5-HT4 receptor activity, and processes useful for preparing crystalline forms of the compound.Type: ApplicationFiled: November 17, 2010Publication date: August 18, 2011Applicant: THERAVANCE, INC.Inventors: Sean M. Dalziel, Kirsten M. Phizackerley
-
Patent number: 7897775Abstract: The invention provides crystalline forms of the novel benzimidazole-carboxamide 5-HT4 receptor agonist compound, 4-(4-{[(2-isopropyl-1H-benzoimidazole-4-carbonyl)amino]methyl}-piperidin-1-ylmethyl)piperidine-1-carboxylic acid methyl ester. The invention also provides pharmaceutical compositions comprising the crystalline compound, methods of using the compound to treat diseases associated with 5-HT4 receptor activity, and processes useful for preparing crystalline forms of the compound.Type: GrantFiled: October 13, 2009Date of Patent: March 1, 2011Assignee: Theravance, Inc.Inventors: Sean M. Dalziel, Kirsten M. Phizackerley
-
Publication number: 20110034685Abstract: The present invention relates to improved methods of purification of sugars and in particular to a method of preparing lactose. A low purity lactose source such as whey is subjected to a first demineralization step involving either ion-exchange or the addition of divalent metal cations, followed by a second demineralization step where alcohol is added. The invention also relates to lactose produced by this method and products comprising lactose produced by this method.Type: ApplicationFiled: July 12, 2010Publication date: February 10, 2011Inventors: Estelle V. Lifran, Robert W. Sleigh, Robert L. Johnson, Robert J. Steele, James A. Hourigan, Sean M. Dalziel
-
Patent number: 7754876Abstract: The present invention relates to improved methods of purification of sugars and in particular to a method of preparing lactose. A low purity lactose source such as whey is subjected to a first demineralization step involving either ion-exchange or the addition of divalent metal cations, followed by a second demineralization step where alcohol is added. The invention also relates to lactose produced by this method and products comprising lactose produced by this method.Type: GrantFiled: December 19, 2001Date of Patent: July 13, 2010Assignee: Dairy Australia LimitedInventors: Estelle V. Lifran, Robert W. Sleigh, Robert L. Johnson, Robert J. Steele, James A. Hourigan, Sean M. Dalziel
-
Publication number: 20100144881Abstract: The invention provides crystalline solid forms of (S)-4-((2S,3S)-7-carbamoyl-1,1-diethyl-3-methoxy-1,2,3,4-tetrahydronaphthalen-2-ylamino)-2-cyclohexylmethyl-butyric acid. The invention also provides pharmaceutical compositions comprising such crystalline solid forms, methods of using such crystalline solid forms to treat diseases associated with mu opioid receptor activity, and processes useful for preparing such crystalline solid forms.Type: ApplicationFiled: December 9, 2009Publication date: June 10, 2010Inventors: Sean M. Dalziel, Miroslav Rapta
-
Publication number: 20100035921Abstract: The invention provides novel 8-azabicyclo[3.2.1]octane compounds of formula (I): wherein R1, R2, R3, A, and G are defined in the specification, or a pharmaceutically-acceptable salt or solvate thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.Type: ApplicationFiled: October 14, 2009Publication date: February 11, 2010Applicant: THERAVANCE, INC.Inventors: Daniel D. Long, Timothy J. Church, John R. Jacobsen, Lan Jiang, Daisuke Roland Saito, Ioanna Stergiades, Priscilla M. Van Dyke, Sean M. Dalziel, Leticia Maria Preza
-
Publication number: 20100029946Abstract: The invention provides crystalline forms of the novel benzimidazole-carboxamide 5-HT4 receptor agonist compound, 4-(4-{[(2-isopropyl-1H-benzoimidazole-4-carbonyl)amino]methyl}-piperidin-1-ylmethyl)piperidine-1-carboxylic acid methyl ester. The invention also provides pharmaceutical compositions comprising the crystalline compound, methods of using the compound to treat diseases associated with 5-HT4 receptor activity, and processes useful for preparing crystalline forms of the compound.Type: ApplicationFiled: October 13, 2009Publication date: February 4, 2010Applicant: THERAVANCE, INC.Inventors: Sean M. Dalziel, Kirsten M. Phizackerley